Departament de Bioquímica i Biotecnologia, Unitat de Nutrició, Universitat Rovira i Virgili, Reus, Spain.
Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Spain.
Am J Nephrol. 2021;52(1):45-58. doi: 10.1159/000513664. Epub 2021 Feb 8.
Large randomized trials testing the effect of a multifactorial weight-loss lifestyle intervention including Mediterranean diet (MedDiet) on renal function are lacking. Here, we evaluated the 1-year efficacy of an intensive weight-loss intervention with an energy-reduced MedDiet (erMedDiet) plus increased physical activity (PA) on renal function.
Randomized controlled "PREvención con DIeta MEDiterránea-Plus" (PREDIMED-Plus) trial is conducted in 23 Spanish centers comprising 208 primary care clinics. Overweight/obese (n = 6,719) adults aged 55-75 years with metabolic syndrome were randomly assigned (1:1) to an intensive weight-loss lifestyle intervention with an erMedDiet, PA promotion, and behavioral support (intervention) or usual-care advice to adhere to an energy-unrestricted MedDiet (control) between September 2013 and December 2016. The primary outcome was 1-year change in estimated glomerular filtration rate (eGFR). Secondary outcomes were changes in urine albumin-to-creatinine ratio (UACR), incidence of moderately/severely impaired eGFR (<60 mL/min/1.73 m2) and micro- to macroalbuminuria (UACR ≥30 mg/g), and reversion of moderately (45 to <60 mL/min/1.73 m2) to mildly impaired GFR (60 to <90 mL/min/1.73 m2) or micro- to macroalbuminuria.
After 1 year, eGFR declined by 0.66 and 1.25 mL/min/1.73 m2 in the intervention and control groups, respectively (mean difference, 0.58 mL/min/1.73 m2; 95% CI: 0.15-1.02). There were no between-group differences in mean UACR or micro- to macroalbuminuria changes. Moderately/severely impaired eGFR incidence and reversion of moderately to mildly impaired GFR were 40% lower (HR 0.60; 0.44-0.82) and 92% higher (HR 1.92; 1.35-2.73), respectively, in the intervention group.
The PREDIMED-Plus lifestyle intervention approach may preserve renal function and delay CKD progression in overweight/obese adults.
目前缺乏大规模随机试验来测试包括地中海饮食(MedDiet)在内的多因素减肥生活方式干预对肾功能的影响。在此,我们评估了能量减少的地中海饮食(erMedDiet)加体力活动(PA)增加的强化减肥干预对肾功能的 1 年疗效。
在西班牙 23 个中心的 208 个初级保健诊所中进行了随机对照的“预防地中海饮食加”(PREDIMED-Plus)试验。共有 6719 名年龄在 55-75 岁之间的超重/肥胖(BMI≥25)、代谢综合征成年人被随机分为强化减肥生活方式干预组(干预组)和常规护理组(对照组),干预组采用能量减少的地中海饮食、体力活动促进和行为支持,对照组接受坚持能量无限制的地中海饮食的常规护理。1 年的主要结局是估算肾小球滤过率(eGFR)的变化。次要结局包括尿白蛋白/肌酐比值(UACR)、中重度 eGFR 降低(<60 mL/min/1.73 m2)和微量白蛋白尿/大量白蛋白尿(UACR≥30 mg/g)的发生率,以及中度(45 至<60 mL/min/1.73 m2)到轻度 eGFR 降低(60 至<90 mL/min/1.73 m2)或微量白蛋白尿/大量白蛋白尿的逆转。
1 年后,干预组和对照组的 eGFR 分别下降了 0.66 和 1.25 mL/min/1.73 m2(平均差异,0.58 mL/min/1.73 m2;95%CI:0.15-1.02)。两组之间的平均 UACR 或微量白蛋白尿/大量白蛋白尿变化没有差异。中重度 eGFR 降低的发生率和中度至轻度 eGFR 降低的逆转率分别降低了 40%(HR 0.60;0.44-0.82)和 92%(HR 1.92;1.35-2.73)。
超重/肥胖成年人采用 PREDIMED-Plus 生活方式干预方法可能有助于保护肾功能和延缓慢性肾脏病进展。